ALEXANDER
Mucus Permeating Nanoparticulate Drug Delivery Systems
| Coordinatore | DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E.V.
Organization address
address: Theodor-Heuss-Allee 25 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 11˙025˙993 € |
| EC contributo | 8˙098˙202 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2011-LARGE-5 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-04-01 - 2016-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
DECHEMA GESELLSCHAFT FUER CHEMISCHE TECHNIK UND BIOTECHNOLOGIE E.V.
Organization address
address: Theodor-Heuss-Allee 25 contact info |
DE (FRANKFURT) | coordinator | 1˙387˙690.45 |
| 2 |
UNIVERSIDAD DE NAVARRA
Organization address
address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL contact info |
ES (PAMPLONA) | participant | 728˙634.80 |
| 3 |
UNIVERSITAET INNSBRUCK
Organization address
address: INNRAIN 52 contact info |
AT (INNSBRUCK) | participant | 692˙998.80 |
| 4 |
SAGETIS BIOTECH SL
Organization address
address: VIA AUGUSTA 390 contact info |
ES (BARCELONA) | participant | 674˙182.00 |
| 5 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | participant | 613˙000.00 |
| 6 |
THIOMATRIX FORSCHUNGS UND BERATUNGS GMBH
Organization address
address: UNTERER PLATZ 22 contact info |
AT (ST VEIT AN DER GLAN) | participant | 605˙000.00 |
| 7 |
EVONIK INDUSTRIES AG
Organization address
address: RELLINGHAUSER STRASSE 1-11 contact info |
DE (ESSEN) | participant | 584˙589.50 |
| 8 |
ARISTOTELIO PANEPISTIMIO THESSALONIKIS
Organization address
address: Administration Building, University Campus contact info |
EL (THESSALONIKI) | participant | 580˙744.40 |
| 9 |
INSTITUT JOZEF STEFAN
Organization address
address: Jamova 39 contact info |
SI (LJUBLJANA) | participant | 565˙000.00 |
| 10 |
UNIVERSITY OF GREENWICH
Organization address
address: "Old Royal Naval College, Park Row, Greenwich" contact info |
UK (LONDON) | participant | 472˙130.96 |
| 11 |
LEK FARMACEVTSKA DRUZBA DD
Organization address
address: VEROVSKOVA ULICA 57 contact info |
SI (LJUBLJANA) | participant | 343˙997.00 |
| 12 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA 1 E contact info |
FI (Kuopio) | participant | 300˙739.62 |
| 13 |
CARDIFF UNIVERSITY
Organization address
address: Newport Road 30-36 contact info |
UK (CARDIFF) | participant | 232˙891.20 |
| 14 |
NANOMI BV
Organization address
address: ZUTPHENSTRAAT 51 contact info |
NL (OLDENZAAL) | participant | 119˙835.00 |
| 15 |
BOEHRINGER INGELHEIM INTERNATIONALGMBH
Organization address
address: BINGER STRASSE contact info |
DE (INGELHEIM) | participant | 116˙100.00 |
| 16 |
CROMA-PHARMA GMBH
Organization address
address: INDUSTRIZEILE 6 contact info |
AT (LEOBENDORF) | participant | 80˙668.27 |
| 17 |
MERCK SERONO SPA
Organization address
address: VIA CASILINA 125 contact info |
IT (ROMA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The objective of the ALEXANDER project is the identification of novel strategies (e.g., proteolytic enzyme strategy, thiomer strategy, zeta potential changing systems, SNEDDS strategy) and the optimization of existing strategies (e.g., disulfide breaking strategy and slippery surface strategy) for the efficient transport of nanocarriers through the mucus gel layer (e.g., intestinal, nasal, ocular, vaginal, buccal, pulmonary). In particular, R&D activities will be focused on the synthesis of functionalized nanocarriers capable of permeating the mucus gel layer and delivering their therapeutic payload to the epithelium. The nanocarriers will be characterized with respect to their physicochemical properties, ability to cross the mucus gel layer, in vitro and in vivo cytotoxicity. The potential of the developed nanocarriers as delivery systems for mucosal administration of macromolecules will be demonstrated via the oral delivery of peptides, oligosaccharides and oligonucleotides and the nasal delivery of a plasmid encoding for an antigen.'
Introduzione (Teaser)
Pharmaceutical companies are looking into nanoparticle drug delivery systems to improve drug performance and treatment efficacy. Optimising delivery and increasing bioavailability of macromolecular drugs should enable the commercialisation of such systems.